Search research articles
Contact Us
Filters
Showing results (111-120 of 116) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 116 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 5, 2011
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort
Seiji Yano, Tadaaki Yamada, Shinji Takeuchi, et al.
Nature Communications
|
January 18, 2019
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, et al.
Nature Communications
|
September 15, 2020
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
Rong Wang, Tadaaki Yamada, Kenji Kita, et al.
Nature Communications
|
August 12, 2018
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Rajeswara Rao Arasada, Konstantin Shilo, Tadaaki Yamada, et al.
Analytical Chemistry
|
August 26, 2024
A Supramolecular Biosensor for Rapid and High-Throughput Quantification of a Disease-Associated Niacin Metabolite
Masaya Ueno, Hiroki Sugiyama, Feng Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC
Timothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 116) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 116 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 5, 2011
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort
Seiji Yano, Tadaaki Yamada, Shinji Takeuchi, et al.
Nature Communications
|
January 18, 2019
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, et al.
Nature Communications
|
September 15, 2020
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
Rong Wang, Tadaaki Yamada, Kenji Kita, et al.
Nature Communications
|
August 12, 2018
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Rajeswara Rao Arasada, Konstantin Shilo, Tadaaki Yamada, et al.
Analytical Chemistry
|
August 26, 2024
A Supramolecular Biosensor for Rapid and High-Throughput Quantification of a Disease-Associated Niacin Metabolite
Masaya Ueno, Hiroki Sugiyama, Feng Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC
Timothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
Page
of 12